

Accepted Manuscript

Title: Lipase-immobilized magnetic chitosan nanoparticles for kinetic resolution of (*R,S*)-ibuprofen

Author: Tomasz Siódmiak Marta Ziegler-Borowska Michał Piotr Marszałł



PII: S1381-1177(13)00107-0
DOI: <http://dx.doi.org/doi:10.1016/j.molcatb.2013.04.008>
Reference: MOLCAB 2667

To appear in: *Journal of Molecular Catalysis B: Enzymatic*

Received date: 14-12-2012
Revised date: 8-4-2013
Accepted date: 15-4-2013

Please cite this article as: T. Siódmiak, M. Ziegler-Borowska, M.P. Marszałł, Lipase-immobilized magnetic chitosan nanoparticles for kinetic resolution of (*R,S*)-ibuprofen, *Journal of Molecular Catalysis B: Enzymatic* (2013), <http://dx.doi.org/10.1016/j.molcatb.2013.04.008>


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Highlights

- Chitosan – poly [N-benzyl-2-(methacryloxy)-N,N -dimethyl-ethanaminium bromide] coated magnetic nanoparticles were prepared
- High enantioselectivity of kinetic resolution of (*R,S*)-ibuprofen was obtained with the use of lipase-immobilized chitosan magnetic nanoparticles
- The sulfo-NHS/EDC-activated magnetic particles provide easy recovery and reuse of lipase.
- Baseline resolution obtained for all analyzed compounds using chiral stationary phases

Accepted Manuscript

Graphical abstract



1 **Lipase-immobilized magnetic chitosan nanoparticles for kinetic resolution**
2 **of (*R,S*)-ibuprofen**

3
4 Tomasz Siódmiak^a, Marta Ziegler-Borowska^b, Michał Piotr Marszałł^{a*}
5
6

7 ^a Department of Medicinal Chemistry, Collegium Medicum in Bydgoszcz, Faculty of Pharmacy, Nicolaus
8 Copernicus University, Dr. A. Jurasza 2, 85-089 Bydgoszcz, Poland

9 ^b Chair of Chemistry and Photochemistry of Polymers, Faculty of Chemistry, Nicolaus Copernicus University,
10 Gagarina 7, 87-100 Toruń, Poland
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 *Corresponding author. Tel.: +48 52 5853540; fax: +48 525853529; e-mail address:
46 mmars@cm.umk.pl (M.P. Marszałł); work address: Collegium Medicum in Bydgoszcz,
47 Jurasza 2, 85-089 Bydgoszcz, Poland
48
49
50

Abstract

Chitosan (CS) – poly [*N*-benzyl-2-(methacryloxy)-*N,N* –dimethylethanaminium bromide] coated magnetic nanoparticles were prepared by co-precipitation method via epichlorohydrin CS cross-linking reaction and were used in the kinetic resolution of (*R,S*)-ibuprofen by enantioselective esterification. Enzyme immobilized onto the surface of the new magnetic supports with the use of *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride (EDC)/*N*-hydroxysulfo-succinimide sodium salt (sulfo-NHS) procedure demonstrated high catalytic activity that allowed to obtain (*S*)-methyl ester of ibuprofen with high enantioselectivity (*E*=50.6). The chiral compounds resulted from the application of magnetic nanoparticles were analyzed with the use of chiral stationary phases. It should be emphasized, that the main advantage of the support is the possibility to magnetically recovery and effective separation (even up to 5 sec.) from the reaction mixture with the use of magnet. The properties of magnetic particles allow for better optimization and may reduce the total costs of the esterification reaction of ibuprofen. Moreover, the application of lipase-immobilized magnetic supports enables to maintain high enantioselective activity after repeatedly use.

Keywords

Keywords: *Candida rugosa* lipase; chitosan magnetic nanoparticles; (*R,S*)-ibuprofen; immobilization; kinetic resolution.

1. Introduction

The development a new strategies for synthesis of enantiomerically pure compounds is still an open challenge in the chemical and pharmaceutical industry [1]. The biotechnology is an alternative approach offering more environmentally and economically attractive way to obtain bioactive and valuable compounds. Lipases are very suitable enzymes for organic synthesis because of their capacity of catalysing different reactions such as asymmetric esterification, asymmetric transesterification and asymmetric hydrolysis [2,3]. These enzymes have been used in the resolution of racemic mixture for the preparation of optically pure compounds [4-8]. Because of their low stability the application of lipases in the industry is limited. Therefore, many lipase immobilization techniques have been employed [9-11]. The most important factors that should be taken into account in the selection of the immobilization strategy include: good catalytic activity, stability and reusability of the enzymes. Numerous

87 reports on the immobilization of lipase techniques onto different supports have been
88 published so far [12-18]. The main advantage of using lipase-immobilized magnetic particles
89 is the ability to recover them from the reaction medium and thus reduce the costs of the
90 reaction, which might be of special importance for the chemical and pharmaceutical industry
91 [19-21]. Most recently, the magnetic particles technology has been found to be a convenient
92 tool for separation of any molecule or protein that has an affinity for the immobilized material
93 onto the surface of magnetic supports [22-24].

94 Triiron tetraoxide magnetic nanoparticles, with their potential application for enzyme
95 immobilization have attracted much attention because of their interesting and preferable
96 physical and chemical properties, such as stability, biocompatibility and superparamagnetism.
97 The special importance is that the surface properties can be modified depending on the
98 immobilized enzyme and reaction medium [25,26]. Polymeric coatings on magnetite
99 nanoparticles have a high potential in several areas of applications especially for organic
100 catalysis and bio-separation. One of the most interesting polymer for magnetic nanoparticles
101 coating is chitosan, a product obtained by partial deacetylation of chitine in alkaline
102 conditions [27]. It is a polycationic polymer with a specific structure and properties. Its
103 biocompatibility and the presence of readily functionalizable groups (amino and hydroxyl)
104 allows such material to be used in biomedical and synthetic applications.

105 2-Arylpropionic acids (profens) are known as major nonsteroidal anti-inflammatory
106 drugs (NSAID) used in the treatment of headache, rheumatoid arthritis, cephalgia, muscular
107 strain [28-30]. All those profen drugs have the chiral carbon atom within the propionic acid
108 moiety. Kinetic resolution of profens is important from the pharmacological point of view
109 because enantiomers of these drugs demonstrate different therapeutic activities. One of the
110 most frequently used drugs within this therapeutic group is (*R,S*)- ibuprofen. The (*S*)-
111 enantiomer of this drug is 160 times more active than its (*R*)- enantiomer in the *in vitro*
112 inhibition of prostaglandin synthesis. Additionally, the latter contributes to increased side
113 effects affecting to the gastrointestinal tract, normal lipids metabolism and membrane
114 function [31,32].

115 In the present study, lipase-immobilized magnetic nanoparticles for the resolution of
116 (*R,S*)-ibuprofen and its esters have been studied. The tested “enzyme magnetic supports” were
117 assessed as potential technique to obtain (*S*)- esters of ibuprofen. Superparamagnetic triiron
118 tetraoxide nanoparticles grafted with chitosan and amphiphilic polymer have been synthesized
119 by co-precipitation of iron oxide in the presence of these polymers. The optimization of
120 immobilization conditions of lipase onto EDC/sulfo-NHS-activated chitosan magnetic

121 nanoparticles was performed as well as the amount and activity of immobilized lipase was
122 determined. The chiral compounds obtained as a result of the application of magnetic supports
123 were analyzed with the use of chiral stationary phases. The optimization of chiral
124 chromatographic conditions involved the selection of stationary phases, mobile phase
125 composition, flow rate, volume of injected analytes and temperature of chromatographic
126 process.

127 **2. Material and methods**

128

129 *2.1. Chemicals*

130

131 (*R,S*)-ibuprofen, (*S*)-ibuprofen, *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide
132 hydrochloride (EDC), *N*-hydroxysulfo-succinimide sodium salt (sulfo-NHS), *n*-hexane, iron
133 (II) chloride tetrahydrate, iron (III) chloride hexahydrate, chitosan (low molecular weight),
134 acetic acid, sodium hydroxide, benzyl bromide, 2-(dimethylamino)ethylmethacrylate and
135 Bradford reagent were purchased from Sigma-Aldrich Co. (Stainhaim, Germany). 2-propanol,
136 cyclohexane, sodium sulphate anhydrous, sodium sulphate decahydrate, molecular sieves 4Å,
137 sodium phosphate dibasic dehydrate, orthophosphoric acid solution, sodium, other solvents,
138 were purchased from POCH S.A. (Gliwice, Poland). Gum Arabic and olive oil were
139 purchased from local source. The (*R*)- and (*S*)-esters of ibuprofen were obtained by the
140 products of standard esterification reaction of (*R,S*)-ibuprofen and (*S*)-ibuprofen with
141 appropriate alcohols (methanol, ethanol, *n*-propanol, *n*-butanol) using sulphuric acid (H₂SO₄)
142 as catalyst [33]. Lipase OF from *Candida rugosa* (activity 380,000 units/g solid) was a gift
143 from Meito Sangyo Co., LTD. (Japan). AIBN (2,2'-Azobis(2-methylpropionitrile) was
144 recrystallized from ethanol before use. All supernatants were separated from magnetic
145 nanoparticles using a magnetic separator Dynal MPC-S (Invitrogen Corporation, Carlsbad,
146 CA, USA). Water used in the study was prepared using a Milli-QWater Purification System
147 (Millipore, Bedford, MA, USA). All incubations were performed at adjusted temperature and
148 number of rotations (600 rpm) in Thermomixer comfort (Eppendorf Co, Germany).
149 Experiments with air and moisture sensitive materials were carried under nitrogen
150 atmosphere. Glassware was oven dried for several hours, assembled hot, and cooled in a
151 stream of nitrogen.

152

153

154

155

156 2.2. Instrumentation

157
158 The Shimadzu HPLC system (Japan) equipped with solvent delivery pump LC-20AD
159 combined with gradient systems, UV-VIS detector model SPD-20A, degasser model DGU-
160 20A5, an autosampler model SIL-20ACHT and a column oven model CTO-10ASVP. Lux
161 Cellulose-1 (LC-1) (4.6mm x 250 mm x 5 μ m) column with cellulose tris(3,5-
162 dimethylphenylcarbamate) stationary phase, Lux Cellulose-2 (LC-2) (4.6mm x 250 mm x
163 5 μ m) column with cellulose tris(3-chloro-4-methylphenylcarbamate) stationary phase, Lux
164 Cellulose-3 (LC-3) (4.6mm x 250 mm x 5 μ m) column with cellulose tris(4-methylbenzoate)
165 stationary phase, Lux Amylose-2 (LA-2) (4.6mm x 250 mm x 5 μ m) column with amylose
166 tris(5-chloro-2-methylphenylcarbamate) stationary phase and Guard Cartridge System model
167 KJO-4282 were purchased from Phenomenex Co. Bradford protein assay method was used
168 with the use of U-1800 Spectrophotometer (Hitachi, Japan).

169 The Fourier Transform Infrared (FTIR) absorption spectra were recorded on Spectrum
170 2000 Perkin Elmer spectrometer in KBr. Melting points were determined with a Büchi SMP
171 32 and Barnstead-Thermolyne Mel-Temp II apparatus in open capillaries and are uncorrected.
172 Scanning electron microscope (SEM) 1430 VP LEO Electron Microscopy Ltd., was used. ¹H
173 and ¹³C NMR spectra were recorded at room temperature with Bruker Avance III 700 and 400
174 MHz spectrometers. Chemical shifts (in ppm) were determined relative to TMS.

175

176 2.3. Chromatographic conditions

177
178 The most appropriate chromatographic conditions for (*R*)- and (*S*)-ibuprofen and their
179 esters were optimized with *n*-hexane/2-propanol/acetic acid (99.6/0.4/0.15 v/v/v) mobile
180 phase at a flow rate of 1 mL/min. Four types of chiral stationary phases were tested, including
181 Lux Cellulose-1, Lux Cellulose-2, Lux Cellulose-3 and Lux Amylose-2 with respect to the
182 peak shape and the chiral resolution. The Lux Cellulose-1 (4.6mm x 250 mm x 5 μ m) HPLC
183 column was chosen as an optimal one for the separation of (*R*)- and (*S*)-ibuprofen and their
184 esters. The chromatographic process was operated at 20°C. The detection UV wavelength was
185 set at 254 nm. **The enantiomeric excess of the substrate (ee_s) and the product (ee_p) as well**
186 **as the conversion (c), enantioselectivity (E) and resolution values (Rs) were calculated**
187 **using the equations described in the literature [34-36].**

188

189 2.4. Preparation of chitosan – poly [*N*-benzyl-2-(methacryloxy)-*N,N*-dimethylethanaminium
190 bromide] coated magnetic nanoparticles

191
192 2.4.1. Synthesis of *N*-benzyl-2-(methacryloyloxy)-*N,N*-dimethylethanaminium bromide (**1**)

193
194 A 2-(dimethylamino)ethyl methacrylate (0.79g, 5mmol) was added dropwise to a
195 solution of benzyl bromide (0.8 g, 5 mmol) in THF (20 mL) with stirring for 20 min at room
196 temperature. A white precipitate formed almost immediately. Next, the mixture was separated
197 by filtration, washed with acetone (3 x 10 mL) and dried under vacuum to gave white solid
198 (mp. 139-142°C) with 95% yield (1.51g).

199 ¹H NMR, DMSO_{d-6}, δ (ppm); 1.92 (s, 3H, CH₃), 3.06 (s, 6H, CH₃), 3.76 (t, *J* = 4.7 Hz, 2H,
200 CH₂), 4.63 (m, 2H, CH₂), 4.69 (m, 2H, CH₂), 5.77 (s, 1H, CH), 6.11 (s, 1H, CH), 7.51- 7.61
201 (m, 5H, CH_{Ar}).

202 ¹³C NMR, DMSO_{d-6}, δ (ppm); 18.40, 49.99, 58.63, 62.82, 67.40, 127.12, 128.46, 129.37,
203 130.78, 133.59, 135.85, 166.35.

204
205 2.4.2. Synthesis of poly [*N*-benzyl-2-(methacryloxy)-*N,N*-dimethylethanaminium] bromide
206 (**PQ**)

207 AIBN (40 mg, 0.2 mmol) was added carefully in 3 portions to a solution of **1** (1.57g, 5
208 mmol) in dry acetonitrile (20mL) at 60°C under nitrogen atmosphere. The mixture was
209 stirred at 60°C under nitrogen for 120h. Insoluble polymer was separated by filtration and
210 washed with methanol (3 x 10 mL) and dried under vacuum at 30°C for 24h to gave polymer
211 with almost 80% yield (1.79g)

212 ¹H NMR, DMSO_{d-6}, δ (ppm); 1.25 (m, 2H, polym. chain), 1.92 (s, 3H, CH₃), 2.20 (s, 6H, N-
213 CH₃), 2.93 (br, 2H, CH₂), 3.40 (m, 2H, CH₂), 4.69 (br, s, 2H, CH₂), 7.51- 7.61 (m, 5H,
214 CH_{Ar}).

215
216 2.4.3. Fe₃O₄-CS - **PQ** magnetic nanoparticles

217
218 0.2 g of poly [*N*-benzyl-2-(methacryloxy)-*N,N*-dimethylethanaminium] bromide was
219 added into solution of chitosan (0.2 g) in 1% acetic acid (20 mL) and mechanically stirred at
220 room temperature for 60 min. Iron (II) chloride tetrahydrate (0.74g, 3.7 mmol), iron (III)
221 chloride hexahydrate (2.02g, 7.5 mmol) were added (1:2 molar ratio) and the resulting
222 solution was chemically precipitated at room temperature by adding dropwise 30% solution of
223 NaOH (7mL). To the black mixture epichlorohydrin (0.2 g, 2.5 mmol) was added and the
224 mixture was mechanically stirred at 50°C for 120 min. The resulting magnetic material were

225 recovered from the suspension by applying a magnet, washed three times with deionized
226 water and dried under vacuum at 50°C for 24 h.

227

228 *2.5. Preparation of lipase-immobilized magnetic nanoparticles*

229

230 *2.5.1. Covalent coupling of lipase using EDC and sulfo-NHS onto chitosan magnetic* 231 *nanoparticles*

232

233 The immobilization of lipase onto the surface of chitosan magnetic nanoparticles was
234 performed by the formation of an amide bond between the carboxyl group of lipase and the
235 primary amino group of the nanoparticle (Scheme 1). The preparation procedure was similar
236 with slightly modifications to previously described method of the immobilization of melanin
237 onto magnetic beads [22]. The 50 mg chitosan magnetic nanoparticles were placed into each
238 of the four 2 mL centrifuge tubes and rinsed three times with 50 mM phosphate buffer (pH
239 6.4). Next, the four solutions of 36.5 mg lipase OF in 1.0 mL of 50 mM phosphate buffer (pH
240 6.4) were prepared. To each of the tubes with lipase the 50 μ L EDC solution in phosphate
241 buffer (2mg/50 μ L) were added. The solutions were incubated at 21°C and shaken for 1 h.
242 After that time 50 μ L of sulfo-NHS solution in phosphate buffer (2.4 mg/50 μ L) was added to
243 each of the tubes containing of lipase and EDC. The solutions were also incubated at 21°C 1 h
244 and shaken. Then, all prepared solutions were transferred into separate centrifuge tubes along
245 with the previously rinsed chitosan magnetic nanoparticles. Next, the resulting mixtures were
246 shaken at 600 rpm in a thermomixer for 2 h at 21°C. At last, lipase-immobilized chitosan
247 nanoparticles were rinsed three times with 0.5 mL of water and were dried overnight at 30°C.
248 The resulted lipase-immobilized magnetic supports were used in the esterification reaction.

249 The amount of immobilized lipase adsorbed onto the magnetic nanoparticles was
250 determined by measuring the initial concentration of lipase and its final concentration in
251 supernatant after immobilization using the Bradford protein assay method [37]. A calibration
252 curve constructed with lipase OF solution of known concentration (0.5-2 mg/mL) was used
253 in the calculation of protein in the initial solution and supernatant. All data used in this
254 formula are average of triplicate of experiments.

255 *2.6. Assay of lipase activity*

256

257 The enzymatic activities of free and immobilized lipase were measured by titration of
258 the fatty acid which came from the hydrolysis of olive oil [38, 39]. A 100 mL of olive oil
259 emulsion was prepared by mixing of olive oil (50 mL) and gum Arabic solution (50 mL, 7%

260 w/v). The assay mixture consisted of emulsion (5 mL), phosphate buffer (2 mL, 100 mM, pH
261 7.4) and free enzyme (1 mL, 6.47 mg/mL) or immobilized lipase (50 mg nanoparticles in 1
262 mL buffer). Oil hydrolysis was carried out at 37°C for 30 min. in a shaking water bath at 150
263 rpm. The reaction was stopped by the addition of 10 mL of ethanol-acetone solution (1:1).
264 The liberated fatty acid in the medium was determined by titration with 50 mM NaOH
265 solution using phenolphthalein indicator. One unit of lipase activity (U) was defined as the
266 amount of enzyme that hydrolyzed olive oil liberating 1 μmol fatty acid per minute under the
267 assay condition. **Activity recovery (%) remaining after immobilization was the ratio**
268 **between the activity of immobilized lipase and the activity of the same amount of free**
269 **lipase in solution that has been immobilized onto magnetic nanoparticles.**

270
271 *2.7. Lipase-immobilized chitosan magnetic nanoparticles in the (R,S)-ibuprofen resolution*

272
273 The reaction mixture was composed of cyclohexane (700 μL), racemic ibuprofen (8.25
274 mg, 0.04 mM) and one of the alcohols: methanol (4.88 μL), ethanol (7.04 μL), *n*-propanol
275 (9.02 μL), *n*-butanol (11.04 μL) as an acyl acceptors. The reaction was started by adding this
276 solution to the magnetic chitosan nanoparticles with immobilized lipase (6.47 mg of lipase) in
277 a 1.5 mL tube (substrate/enzyme ratio – 1.27). The effect of water activity on the
278 esterification reaction was controlled through direct addition of a salt hydrate pair
279 $\text{Na}_2\text{SO}_4/\text{Na}_2\text{SO}_4 \cdot 10\text{H}_2\text{O}$ (35 mg in total, with molar ratio of 1:1) and the molecular sieves
280 4Å. The suspension was incubated at 30°C, shaken (600 rpm) for 140 h in a thermomixer.
281 The samples were withdrawn after 50 h, 100 h and 140 h. The collected supernatant was
282 removed by evaporation at room temperature and the residue was dissolved in 0.7 mL mobile
283 phase and injected (25 μL) into HPLC. The esterification reactions of racemic ibuprofen with
284 alcohols are shown in Scheme 2.

285 To investigate the reusability of immobilized lipase, after each catalytic cycle lipase-
286 immobilized magnetic nanoparticles were washed three times with cyclohexane and then were
287 air dried overnight to remove the organic solvent. Next, magnetic supports were placed into a
288 fresh medium containing a mixture of methanol (4.88 μL), (*R,S*)-ibuprofen (8.25 mg), salt
289 hydrate pair $\text{Na}_2\text{SO}_4/\text{Na}_2\text{SO}_4 \cdot 10\text{H}_2\text{O}$ (35 mg in total) and molecular sieves 4Å in
290 cyclohexane (700 μL).

291

292 **3. Results and discussion**

293

294 3.1. *Characterization of chitosan – poly [N-benzyl-2-(methacryloxy)-N,N -dimethyl-*
295 *ethanaminium bromide] coated magnetic nanoparticles*

296
297 Amphiphilic polymer - (poly [N-benzyl-2-(methacryloxy)-N,N-dimethylethan-
298 aminium bromide) (PQ) has been prepared from N-benzyl-2-(methacryloxy)-N,N-
299 dimethylethanaminium bromide (**1**) as a substrate via free radical polymerization with AIBN
300 as an initiator. Polymerization was performed in nitrogen atmosphere and poly [N-benzyl-2-
301 (methacryloxy)-N,N-dimethylethanaminium] was synthesized with 80% yield after 120 h
302 reaction.

303 Magnetite (Fe₃O₄)-chitosan (CS) - poly [N-benzyl-2-(methacryloxy)-N,N –
304 dimethylethanaminium bromide] (PQ) nanoparticles with polymers weight ratio 1:1 were
305 prepared by co-precipitation method via epichlorohydrin CS cross-linking reaction (Figure 1).
306 Because of the surface of magnetite with a negative charge has an affinity toward chitosan,
307 protonated chitosan and quaternized amphiphilic polymer can coat the magnetic Fe₃O₄
308 nanoparticles via electrostatic interactions [40]. The cross-linking of chitosan via
309 epichlorohydrin made polymeric coating more stable without dilution of amino group content
310 onto the surface of nanoparticles.

311 The chemical structure of prepared magnetic nanoparticles has been characterized by
312 FTIR spectroscopy (Figure 2). The spectrum of nanoparticles shows peaks at 3439, 2936 and
313 1078 cm⁻¹ and indicates the stretching vibrations of NH₂ and partially OH group, aliphatic CH
314 and bending vibrations of CO respectively. The characteristic peak for the Fe-O group of
315 magnetite at 598 cm⁻¹ was observed which indicated the successful generation of Fe₃O₄ – CS
316 – PQ particles. Peaks at 1720 cm⁻¹ and at 1330 cm⁻¹ increasing the stretching vibrations of
317 C=O groups and quaternized ammonium groups of polymer PQ. Peak at 1155 cm⁻¹ increase
318 the C-O-C groups from cross-linked chitosan.

319 The surface morphology of prepared nanoparticles is shown in Figure 3. The average
320 size was 25-30 nm and the magnetic nanoparticles were physically aggregated.

321
322 3.2. *Application of lipase-immobilized chitosan magnetic nanoparticles in the esterification of*
323 *(R,S)- ibuprofen with primary alcohols*

324
325 The problem of the stability and recovery of commonly used and novel catalysts in
326 chemistry still exists. A new magnetic nanoparticle-based products were recently introduced
327 for immobilization of different enzymes. But up to date all studies have focused mainly on the

328 optimization of the immobilization process to characterize the size, structure, magnetic
329 activity and amount of the immobilized enzyme using the Bradford method.

330 Immobilization of commercially available lipase OF from *Candida rugosa* onto the
331 chitosan magnetic nanoparticles was performed by procedure via EDC/sulfo-NHS cross-
332 linking reaction. In order to address the issue of advantage of the magnetic nanoparticles
333 support for the biocatalyst, the optical purity of products, enantioselectivity, separation ability
334 of used magnetic tools, as well as amount of immobilized enzyme and lipolytic activity of
335 lipase were determined. Lipase-immobilized chitosan magnetic nanoparticles were applied in
336 the esterification reaction of (*R,S*)-ibuprofen with four primary alcohols: methanol, ethanol, *n*-
337 propanol and *n*-butanol. Enantioselective activity of the used enzyme demonstrates the
338 ability to catalyzing the esterification of the *S*-enantiomer of ibuprofen. Depending on the
339 applied alcohols different effects on the enantioselectivity and conversion of the reactions were
340 observed. It is assumed that the accessibility of the alcohol to the acyl-enzyme intermediate
341 has significant impact on the final reaction yield. Therefore, nature of the alcohol moiety play
342 an important role in the development of the enantioselective esterification reaction catalyzed
343 by lipase. The influence of the alcohol moiety on the lipase activity were reported several
344 times in the literature [41-45]. Because of the fact, that active site of enzyme has hydrophobic
345 character, it is believed that the hydrophobic alcohols are the most appropriate for
346 esterification catalyzed by lipase. Furthermore, the polar alcohols, like methanol or ethanol
347 cause the low conversion, because they are able to dehydrate the enzyme [46]. Based on the
348 results (Table 1), it can be seen, that ethanol has detrimental impact on the enzyme activity,
349 contributing to decrease the enantioselectivity ($E=6.2$). However, what should be emphasized,
350 application of methanol allowed to obtain very high enantioselectivity (enantiomeric
351 excess of product ($ee_p = 93.5\%$) and value of enantioselectivity ($E=50.6$) - higher than with *n*-
352 butanol ($E=18$). The comparison of the enantioselectivity of non- and immobilized forms of
353 lipase OF in similar reaction conditions demonstrates the lower enantioselectivity of lipase in
354 native form for all tested alcohols than for immobilized enzyme. These facts suggest that,
355 immobilization of lipase onto magnetic support affects on enzyme conformation, enabling
356 effective binding fast-reacting enantiomer to the active site of lipase with formation acyl-
357 enzyme intermediate.

358 The addition of a salt hydrate pair $\text{Na}_2\text{SO}_4/\text{Na}_2\text{SO}_4 \cdot 10\text{H}_2\text{O}$ (35 mg in total, with molar
359 ratio of 1:1) and the molecular sieves 4\AA in to the mixture containing (*R,S*)-ibuprofen, alcohol
360 and lipase-immobilized chitosan magnetic nanoparticles allowed to control the water activity.
361 Lipase acts at the interface between hydrophobic and hydrophilic regions, therefore water

362 content is one of the most important factors affecting the enantioselectivity of this enzyme.
363 The small amount of water is needed to retain their active three-dimensional conformation
364 state, stability and active site polarity. During reaction, salt hydrates adsorb water generated
365 as a by-product and simultaneously provide crystallization water to the components
366 maintaining appropriate water activity. Additional, the use of molecular sieves in the reaction
367 improve the adsorption of water.

368 **The amount of lipase immobilized onto the support was found to be 129.4 mg/g**
369 **magnetic nanoparticles with a recovery activity yield of 78%. The high value of activity**
370 **recovery indicates, that much of the protein was immobilized in an active form.** As
371 reported in the literature, the preference for catalyzing by lipase wide range organic acid chain
372 length can be modified by the application of different immobilization procedures and carriers
373 exhibiting different polarity [47-49]. Based on the results, it can be assumed, that application
374 of quaternary amphiphilic polymer in the synthesis of magnetic nanoparticles increases the
375 affinity between lipase and hydrophobic substrates and thereby affects on the lipolytic activity
376 of the immobilized lipase.

377 However, the main advantage of the proposed lipase-immobilized chitosan magnetic
378 nanoparticles is that the immobilized lipase is recoverable magnetically and can be effectively
379 separated from the reaction mixture with the use of magnet, faster than other classical
380 methods (Figure 4). From economic point of view, the reusability of immobilized lipase is an
381 important aspect in industrial applications. Moreover, the fast separation of catalysts (even up
382 to 5 sec.) from mixture of products allows to precisely optimize the esterification reaction of
383 ibuprofen. It should be also noted, that application of lipase-immobilized chitosan magnetic
384 nanoparticles enabled to obtain products with high enantioselectivity for selected alcohols.
385 What is important the “magnetic biocatalyst” has maintained enantioselective activity in
386 repeatedly use (Figure 5). Enantioselective activity of lipase expressed as an enantiomeric
387 excess of products (ee_p) demonstrated high value ($ee_p = 90\%$) after the 5th cycle. The slight
388 decrease in enantioselective activity could be caused by the denaturation or leak of lipase
389 from magnetic nanoparticles. Summarizing the results, it could be concluded that immobilized
390 lipase has good durability and reusability.

391 *3.3. Analysis of (R,S)-ibuprofen and its esters with the use of chiral stationary phases*

392

393 After optimization of chromatographic parameters of the four commercial polysaccharide-
394 based CSPs: Lux Cellulose-1 (LC-1), Lux Cellulose-2 (LC-2), Lux Cellulose-3 (LC-3), Lux
395 Amylose-2 (LA-2) and based on the previously proposed method by Matthijs et al., the final

396 chromatographic conditions for enantioselective separation of (*R,S*)-ibuprofen and its esters
397 with the use of Lux Cellulose-1 column in NPLC was selected (Figure 6) [49,50]. The main
398 aim of the optimization strategy for resolution of these compounds was the acceptable
399 baseline resolution ($R_s > 1.5$), time of analysis and peak shape. Only LC-1 stationary phase
400 allowed to obtain acceptable parameters of enantioseparation. The last three columns (LC-2,
401 LC-3, LA-2) demonstrated lower ability for resolution of (*R,S*)-ibuprofen and its esters
402 ($R_s < 1.5$) or no resolution ($R_s = 0$), long time of the elution and inappropriate peak shapes.
403 Optimized mobile phase for LC-1 was composed with *n*-hexane/2-propanol/ acetic acid
404 (99.6/0.4/0.15 v/v/v) at a flow rate of 1 mL/min. The NPLC analyses were performed at
405 temperature of 20°C. Tested compounds ((*R,S*)-ibuprofen and its esters) were eluted within 32
406 min. and showed appropriate peaks shapes and baseline resolution ($R_s > 1.5$).

407

408 4. Conclusions

409

410 In this study the new synthesized chitosan – poly [*N*-benzyl-2-(methacryloxy)-*N,N* -
411 dimethyl-ethanaminium bromide] magnetic particles were used in the kinetic resolution of
412 (*R,S*)-ibuprofen by enantioselective esterification. Enzyme immobilized onto the new
413 magnetic support demonstrated high catalytic activity and allowed to obtain products of the
414 esterification of (*R,S*)-ibuprofen with high enantioselectivity. Additionally, **lipolytic activity**
415 **assay proved high recovery activity (78%) of the immobilized lipase.** What is crucial, the
416 presented “recovering” technique enables the magnetically separation of biocatalyst attached
417 to the nanoparticles from the reaction media and effectively reuse in other reaction (up to 5
418 catalytic cycles). From the commercial point of view the use of lipase-immobilized chitosan
419 magnetic nanoparticles is very important, because of the cost reduction of the reaction, what
420 might be of special importance for the industrial application. It should be noted, that
421 optimized of chromatographic conditions with the used of chiral stationary phases allowed for
422 a baseline resolution ($R_s > 1.5$) of both substrates and products during one chromatographic
423 analysis.

424

425

426 Acknowledgement

427

428 We wish to express our sincere thanks to Meito Sangio Co. (Japan) for the supply of
429 lipase OF. We would also like to thank Bogumiła Kupcewicz, Ph.D., from Department of
430 Inorganic and Analytical Chemistry, Faculty of Pharmacy, Nicolaus Copernicus University

431 (Poland) for performed FTIR analysis. The project was partially supported by research grants:
432 National Science Centre DEC-2011/03/D/NZ7/02296.

433

434

435

436

437 **References**

438

439 [1] D. Muñoz Solano, P. Hoyos, M.J. Harnáiz, A.R. Alcántara, J.M. Sánchez-Montero,

440 *Biores. Technol.* 115 (2012) 196-207.

441 [2] Y.-C. Xie, H.-Z. Liu, J.-Y. Chen, *Biotechnol. Lett.* 20 (5) (1998) 455-458.

442 [3] F.J. Contesini, P.O. Carvalho, *Tetrahedron Asym.* 17 (2006) 2069-2073.

443 [4] R.V. Muralidhar, R. Marchant, P. Nigam, *J. Chem. Technol. Biotechnol.* 76 (2001) 3-8.

444 [5] B.-S. Chen, U. Hanefeld, *J. Mol. Catal. B: Enzym.* 85-86 (2013) 239-242.

445 [6] E.A. Manoel, K.C. Pais, M.C. Flores, L.S. de M. e Miranda, M.A.Z. Coelho, A.B.C.

446 *Simas, D.M.G. Freire, R.O.M.A. de Souza, J. Mol. Catal. B: Enzym.* 87 (2013) 139-143.

447 [7] K.P. Dhake, K.M. Deshmukh, Y.S. Wagh, R.S. Singhal, B.M. Bhanage, *J. Mol. Catal. B:*

448 *Enzym.* 77 (2012) 15-23.

449 [8] G.D. Yadav, S. Devendran, *J. Mol. Catal. B: Enzym.* 81 (2012) 58-65.

450 [9] X. Liu, Y. Guan, R. Shen, H. Liu, *J. Chromatogr. B.* 822 (2005) 91-97.

451 [10] W. Xie, N. Ma, *Energy Fuels* 23 (2009) 1347-1353.

452 [11] J.C. Santos, P.D. Mijone, G.F.M. Nunes, V.H. Perez, H.F. Castro, *Colloids Surf. B:*

453 *Biointerfaces* 61 (2008) 229-236.

454 [12] M. Nasratun, H.A. Said, A. Noraziah, A.N. Abd Alla, *Am. J. Appl. Sci.* 6 (9) (2009)

455 1653-1657.

456 [13] V.C.F. da Silva, F.J. Contesini, P.O. Carvahlo, *J. Ind. Microbiol. Biotechnol.* 36

457 (2009) 949-954.

458 [14] G. Bayramoglu, B. Karagoz, B. Altintas, M.Y. Arica, N. Bicak, *Bioprocess Biosyst.*

459 *Eng.* 34 (2011) 735-746.

460 [15] M.P. Marszałł, T. Siódmiak, *Catal. Comm.* 24 (2012) 80-84.

461 [16] I. Belhaj-Ben Romdhane, Z. Ben Romdhane, A. Gargouri, H. Belghith, *J. Mol. Catal. B:*

462 *Enzym.* 68 (2011) 230-239.

463 [17] D.-H. Zhang, L.-X. Yuwen, C. Li, Y.-Q. Li, *Biores. Technol.* 124 (2012) 223-236.

464 [18] K.P. Dhake, A.H. Karoyo, M.H. Mohamed, L.D. Wilson, B.M. Bhanage, *J. Mol. Catal. B*

- 465 Enzym. 87 (2013) 105-112.
- 466 [19] Y. Liu, S. Jia, Q. Wu, J. Ran, W. Zhang, S. Wu, Catal. Commun. 12 (2011) 717-720.
- 467 [20] Y. Jiang, C. Guo, H. Xia, I. Mahmood, C. Liu, H. Liu, J. Mol. Catal. B: Enzym. 58
468 (2009) 103-109.
- 469 [21] E. Yilmaz, M. Sezgin, M. Yilmaz, J. Mol. Catal. B: Enzym. 69 (2011) 35-41.
- 470 [22] M.P. Marszałł, A. Buciński, K. Goryński, A. Proszowska, R. Kaliszan, J. Chromatogr. A
471 1218 (2011) 229-236.
- 472 [23] R. Moaddel, M.P. Marszałł, F. Bigli, Q. Yang, X. Duan, I.W. Wainer, Anal. Chem. 79
473 (2007) 5414-5417.
- 474 [24] M.P. Marszałł, R. Moaddel, S. Kole. M. Gandhari, M. Bernier, I.W. Wainer, Anal.
475 Chem. 80 (2008) 7571-7577.
- 476 [25] B. Sahoo, S.K. Sahu, P.Pramanik, J. Mol. Catal. B: Enzym. 69 (2011) 95-102
- 477 [26] C.-H. Kuo, Y.-C. Liu, C.-M. J. Chang, J.-W. Chen, C. Chang, C.-J. Shieh, Carbohydr.
478 Polym. 87 (2012) 2538-2545.
- 479 [27] E.I. Rabea, M.E.-T. Badawy, Ch.V. Stevens, G. Smagghe, W. Steurbaut W.
480 Biomacromolecules, 4 (2003) 1457-1464.
- 481 [28] A. Sánchez, F. Valero, J. Lafuente, C. Solá, Enzyme Microb. Technol. 27 (2000) 157-
482 166.
- 483 [29] R. Morrone, N. D'Antona, D. Lambusta, G. Nicolosi, J. Mol. Catal. B: Enzym. 65 (2010)
484 49-51.
- 485 [30] K. Kato, Y. Gong, T. Saito, H. Kimoto, J. Biosci. Bioeng. 90 (3) (2000) 332-334.
- 486 [31] Y. Liu, F. Wang, T. Tan, J. Mol. Catal. B: Enzym. 56 (2009) 126-130.
- 487 [32] D. Chávez-Flores, J.M. Salvador, Biotechnol. J. 4 (2009) 1222-1224.
- 488 [33] A. Ghanem, M.N. Aboul-Enein, A. El-Azzouny, M.F. El-Beairy, J. Chromatogr. A.
489 1217 (2010) 1063-1074.
- 490 [34] C.-S. Chen, Y. Fujimoto, G. Girdaukas, C.J. Sih, J. Am. Chem. Soc. 104 (1982)
491 7294-7299.
- 492 [35] A. Ghanem, H.Y. Aboul-Enein, Chirality 17 (2005) 1-15.
- 493 [36] The United States Pharmacopeia, USP 25, NF 20, United States Pharmacopeial
494 Convention, Rockville, MD, 2002, p. 1991.
- 495 [37] Bradford M. M., Anal. Biochem. 72 (1976) 248-254.
- 496 [38] G. Bayramoglu, M.Y. Arica, J. Mol. Catal. B: Enzym. 55 (2008) 76-83.

- 497 [39] D.-H. Zhang, L.-X. Yuwen, Y.-L. Xie, W. Li, X.-B. Li, *Colloids Surf. B Biointerfaces* 89
498 (2012) 73-78.
- 499 [40] D.L. Zhao, X.X. Wang, X.W. Zeng, Q.S. Xia, J.T. Tang, *J. Alloys Compd.* 477 (1-2)
500 (2009) 739-743.
- 501 [41] I.J. Colton, D.L.T. Yin, P. Grochulski, R.J. Kazlauskas, *Adv. Synth. Catal.* 353 (2011)
502 2529-2544.
- 503 [42] R.V. Muralidhar, R. Marchant, R. Nigam, *J. Chem. Technol. Biotechnol.* 76 (2001) 3-8.
- 504 [43] A. Mustranta, *Appl. Microbiol. Biotechnol.* 38 (1992) 61-66.
- 505 [44] M.L. Foresti, M. Galle, M.L. Ferreira, L.E. Briand, *J. Chem. Technol. Biotechnol.* 84
506 (2009) 1461-1473.
- 507 [45] X. Meng, G. Xu, Q.-L. Zhou, J.-P. Wu, L.-R. Yang, *J. Mol. Catal. B: Enzym.* 89 (2013)
508 86-92.
- 509 [46] Y. Liu, F. Wang, T. Tan, *J. Mol. Catal. B: Enzym.* 56 (2009) 126-130.
- 510 [47] L. Chronopoulou, G. Kamel, C. Sparago, F. Bordi, S. Lupi, M. Diociaiuti, C. Palocci,
511 *Soft Matter* 7 (2011) 2653-2662.
- 512 [48] J.C. Santos, T. Bueno, P.C. Molgero da Ros, H.F. de Castro, *J. Chem. Technol.*
513 *Biotechnol.* 82 (2007) 956-961.
- 514 [49] Y. Jiang, C. Guo, H. Xia, I. Mahmood, C. Liu, H. Liu, *J. Mol. Catal. B: Enzym.* 58
515 (2009) 103-109.
- 516 [50] T. Siódmiak, J.K. Rumiński, M.P. Marszał, *Curr. Org. Chem.* 16 (2012) 972-977.
- 517 [51] N. Matthijs, C. Perrin, M. Maftouh, D.L. Massart, Y. Vander Heyden, *J. Chromatogr. A*
518 1041 (2004) 119-133.
- 519
- 520
- 521
- 522
- 523
- 524
- 525
- 526
- 527
- 528
- 529
- 530

531 **Figure legends**

532

533

534 Scheme 1. Immobilization of lipase using EDC and sulfo-NHS onto the surface of chitosan
535 magnetic nanoparticles.

536

537 Scheme 2. The enantioselective esterification of racemic ibuprofen with alcohols (methanol,
538 ethanol, *n*-propanol, *n*-butanol) with the use of lipase-immobilized
539 superparamagnetic triiron tetraoxide nanoparticles.

540

541 Figure 1. Superparamagnetic triiron tetraoxide nanoparticle with chitosan and amphiphilic
542 polymer cross-linked by epichlorohydrin.

543

544 Figure 2. FTIR spectrum of the Fe₃O₄ – CS – PQ nanoparticles.

545

546 Figure 3. SEM image of magnetic nanoparticles: chitosan and amphiphilic polymer in
547 weight ratio 1:1 cross-linked by epichlorohydrin.

548 Figure 4. Magnetic nanoparticles with immobilized lipase dispersed in the reaction medium:

549

a) without magnet; b) attracted by magnet.

550 Figure 5. Effect of the reuse of lipase (OF)-immobilized chitosan magnetic nanoparticles on
551 the enantioselectivity of the esterification of (*R,S*)-ibuprofen. Reaction conditions:
552 (*R,S*)-ibuprofen (8.25 mg), methanol (4.88 μ L), immobilized lipase OF (50 mg of
553 magnetic nanoparticles), salt hydrate pair Na₂SO₄/Na₂SO₄ · 10H₂O (totally 35mg, with
554 molar ratio of 1:1), molecular sieves 4 \AA , cyclohexane (700 μ L), temp. 30 $^{\circ}$ C, after 140
555 h.

556 Figure 6. HPLC chromatograms of ibuprofen and its esters: A) *R*-enantiomer of methyl ester
557 (t_R =5.518), *S*-enantiomer of methyl ester (t_R =6.132), *R*-ibuprofen (t_R =25.010) and
558 *S*-ibuprofen (t_R =29.758); B) *R*-enantiomer of ethyl ester (t_R =5.184), *S*-enantiomer
559 of ethyl ester (t_R =5.600), *R*-ibuprofen (t_R =25.026) and *S*-ibuprofen (t_R =29.831); C)
560 *R*-enantiomer of *n*-propyl ester (t_R =4.902), *S*-enantiomer of *n*-propyl ester (t_R
561 =5.281), *R*-ibuprofen (t_R =25.026) and *S*-ibuprofen (t_R =29.920); D) *R*-enantiomer of
562 *n*-butyl ester (t_R =4.798), *S*-enantiomer of *n*-butyl ester (t_R =5.166), *R*-ibuprofen (t_R
563 =24.992) and *S*-ibuprofen (t_R =29.984);

564 Resolution values (R_s): (R,S)- ibuprofen ($R_s=5.45$), (R,S)-ibuprofen methyl ester
565 ($R_s=2.60$), (R,S)-ibuprofen ethyl ester ($R_s=1.94$), (R,S)-ibuprofen *n*-propyl ester
566 ($R_s=1.86$), (R,S)-ibuprofen *n*-butyl ester ($R_s=1.78$);

567 Chromatographic conditions: Lux Cellulose-1 (4.6mm x 250 mm x 5 μ m) column,
568 mobile phase: *n*-hexane/2-propanol/ acetic acid (99.6/0.4/0.15 v/v/v), F=1 mL/min.,
569 $t = 20^\circ\text{C}$, UV= 254 nm.

570

571

572

573

574

575

576

577

578

579

580

Accepted Manuscript

Table 1. The influence of alcohols on the conversion and the enantioselectivity of the esterification reaction of (*R,S*)-ibuprofen with the application of lipase OF-immobilized superparamagnetic triiron tetraoxide nanoparticles.

Alcohol	ee _p (%)	ee _s (%)	C (%)	E
Methanol	93.5	54.0	36.7	50.6
Ethanol	61.7	40.0	39.3	6.2
<i>n</i> -Propanol	68.3	54.1	44.2	9.1
<i>n</i> -Butanol	76.5	79.1	50.8	18.0

Reaction conditions: racemic ibuprofen (8.25 mg, 0.04 mM), one of the alcohols: methanol (4.88 μ L), ethanol (7.04 μ L), *n*-propanol (9.02 μ L), *n*-butanol (11.04 μ L), lipase OF-immobilized superparamagnetic triiron tetraoxide nanoparticles, cyclohexane (700 μ L), Na₂SO₄/Na₂SO₄ · 10H₂O (35 mg in total, with molar ratio of 1:1), molecular sieves 4Å; temp. 30°C, shaking 600 rpm.; after 140 h; C-conversion, ee_s - enantiomeric excess of the substrate, ee_p - enantiomeric excess of the product, E - enantioselectivity.

Figure 2.






Figure 3.



Accepted Manuscript

Figure 4.




a)

b)

Accepted Manuscript

Scheme 1.



Amine-terminated chitosan magnetic nanoparticles

Figure 5.






Figure 6.



Scheme 2.



C₁ - Methyl

C₂ - Ethyl

C₃ - *n*-Propyl

C₄ - *n*-Butyl